Chronic Disease Is a $4.5 Trillion Problem. Prevention Gets 3% of the Budget. That’s We Invested In AyuSaige.

Chronic Disease Is a $4.5 Trillion Problem. Prevention Gets 3% of the Budget. That’s We Invested In AyuSaige.

The United States spends $4.5 trillion a year on chronic disease. Diabetes alone accounts for $327 billion of that, across 37 million Americans. PCOS affects 1 in 5 women and remains chronically underdiagnosed, quietly feeding into infertility and diabetes down the line.

Here's the number that should bother everyone in healthcare: less than 3% of health budgets go to prevention. The system is built to treat chronic disease once it's expensive, not to stop it from becoming expensive in the first place.

Why Prevention Keeps Losing

It's not that personalized, preventive care doesn't exist. It's that it doesn't scale.

The gold standard for managing a condition like PCOS or diabetes is a real practitioner who knows your history, adjusts your plan as your body changes, and follows up when you fall off track. That works. It also requires a small army of experts per patient, which is exactly why it stays reserved for people with the time, money, and access to assemble it themselves.

Drop the human layer to make it scale, and you get the other failure mode: generic wellness apps that hand everyone the same plan regardless of their diagnosis, their lifestyle, or what's actually working for them. Neither version solves the problem. One is too expensive to reach most people. The other isn't personalized enough to help the people it reaches.

The Missing Layer

What chronic care actually needs is something in between: personalization that comes from AI rather than headcount, backed by real practitioners instead of a generic content library, with a feedback loop that tracks whether the plan is working and adjusts when it isn't.

That's a software problem now in a way it wasn't five years ago. AI can take a health intake the way a practitioner would, build a plan grounded in research rather than a template, and nudge someone daily in a way no clinician has the hours to do. The practitioner still matters. The AI just makes sure the time between visits isn't wasted.

Why We Backed AyuSaige

AyuSaige is built by people who tried the manual version first. Founder Amulya Ravipati ran B2B wellness programs for companies like P&G, Novartis, and Biocon before starting AyuSaige, and watched the same pattern play out again and again: people don't fail their health goals because they lack information, they fail because they lack personalization and accountability, and no wellness provider can scale enough human experts to give everyone both.

AyuSaige's answer is an AI health companion that builds a personalized wellness plan for conditions like PCOS and diabetes, connects users to real practitioners for the parts software shouldn't replace, and tracks progress so the plan keeps adjusting instead of going stale. It's sold primarily to the employers and insurers who carry the cost of chronic conditions directly, and free to the individuals who need it.

The Bigger Bet

Chronic disease is not going to get cheaper on its own, and the current system's answer, more treatment after the fact, is precisely the wrong end of the problem to invest in. The companies that matter here are the ones that make prevention personal enough to actually work and cheap enough to actually scale.

That's the bet we're making with AyuSaige.

‍